tiprankstipranks
Advertisement
Advertisement

CADL Stock Latest News

Candel Therapeutics price target raised to $26 from $22 at Citi
The FlyCandel Therapeutics price target raised to $26 from $22 at Citi
16d ago
CADL
CAN-2409’s Emerging Survival Benefit and Biomarker-Driven Immunotherapy Platform Support Buy Rating and $23 Target
PremiumRatings
CAN-2409’s Emerging Survival Benefit and Biomarker-Driven Immunotherapy Platform Support Buy Rating and $23 Target
17d ago
CADL
Candel Therapeutics’ aglatimagene shows extended long-term survival in NSCLC
PremiumThe Fly
Candel Therapeutics’ aglatimagene shows extended long-term survival in NSCLC
17d ago
CADL
Candel Therapeutics: Strengthened Balance Sheet and Late‑Stage Pipeline Catalysts Support High‑Risk Buy Rating Despite Dilution
PremiumRatings
Candel Therapeutics: Strengthened Balance Sheet and Late‑Stage Pipeline Catalysts Support High‑Risk Buy Rating Despite Dilution
21d ago
CADL
Candel Therapeutics price target lowered to $22 from $24 at Citi
PremiumThe Fly
Candel Therapeutics price target lowered to $22 from $24 at Citi
21d ago
CADL
Restrictive RTW Purchase Agreement Covenants Threaten Candel Therapeutics’ Financial Flexibility and Increase Default Risk
PremiumCompany AnnouncementsRestrictive RTW Purchase Agreement Covenants Threaten Candel Therapeutics’ Financial Flexibility and Increase Default Risk
21d ago
CADL
Candel Therapeutics: Advancing CAN-2409 Toward a 2026 BLA on Strengthening Prostate Cancer Data and Solid Cash Runway
Premium
Ratings
Candel Therapeutics: Advancing CAN-2409 Toward a 2026 BLA on Strengthening Prostate Cancer Data and Solid Cash Runway
22d ago
CADL
Candel Therapeutics: Advancing CAN-2409 Toward BLA With Platform-Like Oncology Potential and Diversified Pipeline Upside
Premium
Ratings
Candel Therapeutics: Advancing CAN-2409 Toward BLA With Platform-Like Oncology Potential and Diversified Pipeline Upside
22d ago
CADL
Candel Therapeutics reports Q4 EPS (54c) vs. (40c) last year
PremiumThe Fly
Candel Therapeutics reports Q4 EPS (54c) vs. (40c) last year
22d ago
CADL
Candel Therapeutics sees cash runway into 1Q28
PremiumThe Fly
Candel Therapeutics sees cash runway into 1Q28
22d ago
CADL
Candel Therapeutics Announces Equity Offering to Fund CAN-2409
PremiumCompany Announcements
Candel Therapeutics Announces Equity Offering to Fund CAN-2409
1M ago
8K
CADL
Candel Therapeutics 18.3M share Spot Secondary priced at $5.45
PremiumThe Fly
Candel Therapeutics 18.3M share Spot Secondary priced at $5.45
1M ago
CADL
Candel Therapeutics 18.3M share Spot Secondary priced at $5.45
PremiumThe FlyCandel Therapeutics 18.3M share Spot Secondary priced at $5.45
1M ago
CADL
Candel Therapeutics announces $100M royalty funding agreement
Premium
The Fly
Candel Therapeutics announces $100M royalty funding agreement
1M ago
CADL
Candel Therapeutics Secures $100M Royalty Funding for CAN-2409
Premium
Company Announcements
Candel Therapeutics Secures $100M Royalty Funding for CAN-2409
1M ago
8K
CADL
Candel Therapeutics announces $100M common stock offering
PremiumThe Fly
Candel Therapeutics announces $100M common stock offering
1M ago
CADL
Candel Therapeutics Advances Gene-Based Prostate Cancer Trial With New Biomarker Update
PremiumCompany Announcements
Candel Therapeutics Advances Gene-Based Prostate Cancer Trial With New Biomarker Update
2M ago
CADL
Candel Therapeutics’ Promising CAN-2409 Program Drives Buy Rating Amid Positive Phase 3 Results and Expert Endorsements
PremiumRatings
Candel Therapeutics’ Promising CAN-2409 Program Drives Buy Rating Amid Positive Phase 3 Results and Expert Endorsements
4M ago
CADL
Candel Therapeutics: Strategic Advancements and Regulatory Progress Support Buy Rating
PremiumRatings
Candel Therapeutics: Strategic Advancements and Regulatory Progress Support Buy Rating
4M ago
CADL
Optimistic Buy Rating for Candel Therapeutics Driven by Promising Pipeline and Strategic Milestones
PremiumRatingsOptimistic Buy Rating for Candel Therapeutics Driven by Promising Pipeline and Strategic Milestones
4M ago
CADL
Candel Therapeutics: Promising Developments Amidst Regulatory and Market Challenges
Premium
Ratings
Candel Therapeutics: Promising Developments Amidst Regulatory and Market Challenges
4M ago
CADL
Candel Therapeutics Hosts Virtual R&D Day on Immunotherapy
Premium
Company Announcements
Candel Therapeutics Hosts Virtual R&D Day on Immunotherapy
4M ago
8K
CADL

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >